Eri L M, Urdal P
Department of Surgery, Ullevaal University Hospital, Oslo, Norway.
Eur Urol. 1995;27(4):274-9. doi: 10.1159/000475180.
The effect of the nonsteroidal antiandrogen Casodex (176334) on a number of risk factors for cardiovascular diseases was investigated in a double-blind, randomized, placebo-controlled study comprising 27 evaluable patients with benign prostatic hyperplasia who received either placebo or Casodex at a dosage of 50 mg daily for 24 weeks. We hypothesized that the 30-35% increase in serum levels of testosterone and estradiol seen during treatment with Casodex might induce changes in various risk factors. We found no statistically significant change in total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglycerides. Apolipoproteins A1 and B also remained unchanged, along with plasma concentrations of fibrinogen and plasminogen activator inhibitor 1. Casodex has the potential to become an important drug for treatment of prostatic diseases. Our study does not suggest that the drug is associated with an increased cardiovascular risk.
在一项双盲、随机、安慰剂对照研究中，对27例可评估的良性前列腺增生患者进行了研究，这些患者接受安慰剂或每天50毫克剂量的康士得（176334）治疗24周，以调查非甾体类抗雄激素药物康士得对多种心血管疾病危险因素的影响。我们假设，在使用康士得治疗期间观察到的睾酮和雌二醇血清水平升高30%-35%可能会引起各种危险因素的变化。我们发现，总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和甘油三酯没有统计学上的显著变化。载脂蛋白A1和B以及纤维蛋白原和纤溶酶原激活物抑制剂1的血浆浓度也保持不变。康士得有可能成为治疗前列腺疾病的重要药物。我们的研究并未表明该药物会增加心血管疾病风险。
